The role of imaging techniques in the management of multiple myelomaZAMAGNI, Elena; CAVO, Michele.British journal of haematology. 2012, Vol 159, Num 5, pp 499-513, issn 0007-1048, 15 p.Article

International conference on multiple myeloma : biology, pathophysiology prognosis and treatment, June 19-22, 1989, Bologna, ItalyTURA, Sante; CAVO, Michele; GOBBI, Marco et al.European journal of haematology. Supplementum. 1989, Vol 51, issn 0902-4506, 195 p.Conference Proceedings

How I treat elderly patients with myelomaMEHTA, Jayesh; CAVO, Michele; SINGHAL, Seema et al.Blood. 2010, Vol 116, Num 13, pp 2215-2223, issn 0006-4971, 9 p.Article

Maintenance therapy in newly diagnosed multiple myeloma: current recommendationsBRIOLI, Annamaria; TACCHETTI, Paola; ZAMAGNI, Elena et al.Expert review of anticancer therapy. 2014, Vol 14, Num 5, pp 581-594, issn 1473-7140, 14 p.Article

The impact of intra-clonal heterogeneity on the treatment of multiple myelomaBRIOLI, Annamaria; MELCHOR, Lorenzo; CAVO, Michele et al.British journal of haematology. 2014, Vol 165, Num 4, pp 441-454, issn 0007-1048, 14 p.Article

First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging StrategiesGUGLIOTTA, Gabriele; CASTAGNETTI, Fausto; APOLINARI, Michela et al.Drugs (Basel). 2014, Vol 74, Num 6, pp 627-643, issn 0012-6667, 17 p.Article

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma―Related Bone DiseaseTERPOS, Evangelos; MORGAN, Gareth; REIMAN, Tony et al.Journal of clinical oncology. 2013, Vol 31, Num 18, pp 2347-2357, issn 0732-183X, 11 p.Article

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideLAROCCA, Alessandra; CAVALLO, Federica; PATRIARCA, Francesca et al.Blood. 2012, Vol 119, Num 4, pp 933-939, issn 0006-4971, 7 p.Article

Extramedullary Intracranial Localization of Multiple Myeloma and Treatment With Novel Agents: A Retrospective Survey of 50 PatientsGOZZETTI, Alessandro; CERASE, Alfonso; FLORIDIA, Michele et al.Cancer. 2012, Vol 118, Num 6, pp 1574-1584, issn 0008-543X, 11 p.Article

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationCAVO, Michele; VINCENT RAJKUMAR, S; SONNEVELD, Pieter et al.Blood. 2011, Vol 117, Num 23, pp 6063-6073, issn 0006-4971, 11 p.Article

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneHAROUSSEAU, Jean-Luc; PALUMBO, Antonio; KOMARNICKI, Mieczyslaw et al.Blood. 2010, Vol 116, Num 19, pp 3743-3750, issn 0006-4971, 8 p.Article

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival : an analysis of 10 549 patients from the International Myeloma Working GroupLUDWIG, Heinz; DURIE, Brian G. M; WESTIN, Jan et al.Blood. 2008, Vol 111, Num 8, pp 4039-4047, issn 0006-4971, 9 p.Article

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma : updated results of a randomized controlled trial. CommentaryDURIE, Brian G. M; PALUMBO, Antonio; ZAMBELLO, Renato et al.Blood. 2008, Vol 112, Num 8, issn 0006-4971, 2998-2999, 3107-3114 [10 p.]Article

Drug Resistance and BCR-ABL Kinase Domain Mutations in Philadelphia Chromosome―Positive Acute Lymphoblastic Leukemia From the Imatinib to the Second-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are in the Type of Mutations, But Not in the Frequency of Mutation InvolvementSOVERINI, Simona; DE BENEDITTIS, Caterina; SICA, Simona et al.Cancer. 2014, Vol 120, Num 7, pp 1002-1009, issn 0008-543X, 8 p.Article

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple MyelomaPALUMBO, Antonio; HAJEK, Roman; CASCAVILLA, Nicola et al.The New England journal of medicine. 2012, Vol 366, Num 19, pp 1759-1769, issn 0028-4793, 11 p.Article

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantationZAMAGNI, Elena; PATRIARCA, Francesca; PANTANI, Lucia et al.Blood. 2011, Vol 118, Num 23, pp 5989-5995, issn 0006-4971, 7 p.Article

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentMORABITO, Fortunato; GENTILE, Massimo; PETRUCCI, Maria Teresa et al.Blood. 2011, Vol 118, Num 22, pp 5759-5766, issn 0006-4971, 8 p.Article

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. CommentaryCAVO, Michele; VINCENT RAJKUMAR, S; FONSECA, Rafael et al.Blood. 2005, Vol 106, Num 13, pp 4018-4019, issn 0006-4971, 6 p.Article

A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myelomaRIA, Roberto; VACCA, Angelo; RUSSO, Francesca et al.Thrombosis and haemostasis. 2004, Vol 92, Num 6, pp 1438-1445, issn 0340-6245, 8 p.Article

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myelomaCORRADINI, Paolo; CAVO, Michele; RUSSELL, Nigel et al.Blood. 2003, Vol 102, Num 5, pp 1927-1929, issn 0006-4971, 3 p.Article

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalPALUMBO, Antonio; BRINGHEN, Sara; GRASSO, Mariella et al.Journal of clinical oncology. 2014, Vol 32, Num 7, pp 634-640, issn 0732-183X, 7 p.Article

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled TrialsSONNEVELD, Pieter; GOLDSCHMIDT, Hartmut; DESAI, Avinash et al.Journal of clinical oncology. 2013, Vol 31, Num 26, pp 3279-3287, issn 0732-183X, 9 p.Article

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapyBRIOLI, Annamaria; BOYD, Kevin D; DAVIES, Faith E et al.British journal of haematology. 2013, Vol 161, Num 2, pp 291-294, issn 0007-1048, 4 p.Article

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized TrialPALUMBO, Antonio; CAVO, Michele; NOZZOLI, Chiara et al.Journal of clinical oncology. 2011, Vol 29, Num 8, pp 986-993, issn 0732-183X, 8 p.Article

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensKUMAR, Shaji; GIRALT, Sergio; SAN MIGUEL, Jesus et al.Blood. 2009, Vol 114, Num 9, pp 1729-1735, issn 0006-4971, 7 p.Article